Evidence map›Paper›PMID 40930009›Full record

ArticleTranslational oncology2025

Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer.

Toru Sakatani, Sunao Tanaka, Kaoru Murakami, Francisco Aguilar, Owen T M Chan, Catherine Bresee, Daniel J Luthringer, Charles J Rosser, Wayne Hogrefe, Hideki Furuya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toru SakataniSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Urology, Kyoto University, Kyoto, Japan. Electronic address: sktntoru5@kuhp.kyoto-u.ac.jp.
Sunao TanakaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Sunao.Tanaka@cshs.org.
Kaoru MurakamiSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Urology, Kyoto University, Kyoto, Japan. Electronic address: kaorum@kuhp.kyoto-u.ac.jp.
Francisco AguilarSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: francisco.aguilar@cshs.org.
Owen T M ChanClinical and Translational Research Program University of Hawaii Cancer Center, Honolulu, HI, USA. Electronic address: ochan@cc.hawaii.edu.
Catherine BreseeBiostatistics Shared Resources, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Catherine.Bresee@cshs.org.
Daniel J LuthringerDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Daniel.luthringer@cshs.org.
Charles J RosserSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Nonagen Bioscience Corp., Los Angeles, CA, USA. Electronic address: Charles.Rosser@cshs.org.
Wayne HogrefeNonagen Bioscience Corp., Los Angeles, CA, USA.
Hideki FuruyaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: hideki.furuya@cshs.org.

Funding

VALIDATION OF A MULTIPLEXED ASSAY FOR BLADDER CANCER DIAGNOSISR01CA198887 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI ROSSER, CHARLES J · 2016 to 2025
$6.8M
A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor BiologyR01CA277810 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Hideki Furuya, Charles J Rosser · 2023 to 2026
$1.6M
APPLICATION OF A MULTIPLEXED IMMUNOASSAY FOR THE DETECTION OF BLADDER CANCERUH3CA271377 · NCI · CEDARS-SINAI MEDICAL CENTER · PI ROSSER, CHARLES J · 2022 to 2024
$1.2M
NCI NIH HHS R01 CA198887NCI NIH HHS R01 CA277810NCI NIH HHS UH3 CA271377
6 · The paper itself

Abstract

Bladder cancer (BC) remains a common malignancy, with muscle-invasive bladder cancer (MIBC) comprising 20 % of cases and a poor 5-year survival rate of ∼50 %. While neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard treatment for locally advanced disease, NAC is limited by toxicity and non-response in many patients. Predictive biomarkers are urgently needed to guide treatment decisions. We developed and analytically validated a multiplex qPCR array to measure mRNA expression of 10 NAC response-associated biomarkers in MIBC. RNA from 8 formalin-fixed paraffin-embedded (FFPE) and 4 fresh-frozen (FF) MIBC specimens was analyzed to assess the effects of tissue type, necrosis, and pre-analytical variables on assay performance. The assay showed high concordance between FF and FFPE samples, with stable performance using FFPE curls stored at ≤4 °C for up to two weeks. It remained robust across RNA input levels (5-100 ng) and required a minimum quality threshold (DV200 >15 %). Necrosis had minimal impact on gene expression, and reproducibility was confirmed across technicians and time points. In conclusion, this qPCR array-based assay offers a reliable platform for evaluating key biomarkers in FFPE tissues and holds promise as a potential clinical tool to predict NAC response in MIBC patients.

Indexed as

Molecular diagnosticMultiplexMuscle invasive bladder cancerNeoadjuvant chemotherapy

Identifiers

PMID40930009
PMCPMC12454996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.